Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years
Sign Up to like & getrecommendations! Published in 2022 at "Nagoya Journal of Medical Science"
DOI: 10.18999/nagjms.84.1.80
Abstract: ABSTRACT More than 40% of Japanese patients with multiple myeloma (MM) are over 75 years of age at diagnosis. Regardless of the treatment benefits, complications and relapses obstruct long-term survival. We conducted a phase II,… read more here.
Keywords: alternating bortezomib; multiple myeloma; dexamethasone lenalidomide; bortezomib dexamethasone ... See more keywords